Prevalence of hepatitis C among pregnant females attending antenatal clinic at a tertiary care hospital in Lucknow, Uttar Pradesh, India

Noor Jahan1, Nitin Chaudhary2*, Asma Nigar3, Siraj Ahmad4, Razia Khatoon5, Anil Kumar6

1Department of Microbiology, Integral Institute of Medical Sciences and Research, Integral University, Lucknow, Uttar Pradesh, India
2Department of Medical Microbiology, Saaii College of Medical Science and Technology, Chaubepur, Kanpur, Uttar Pradesh, India
3Department of Obstetrics and Gynaecology, 4Department of Community Medicine, Integral Institute of Medical Sciences and Research, Integral University, Lucknow, Uttar Pradesh, India
5Department of Microbiology, Hind Institute of Medical Sciences, Mau, Ataria, Sitapur, Uttar Pradesh, India
6Department of Medical Microbiology, Vananchal Dental College and Hospital, Garhwa, Jharkhand, India

Received: 23 November 2019
Revised: 22 December 2019
Accepted: 27 December 2019

*Correspondence:
Nitin Chaudhary.
E-mail: cnitin707@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Hepatitis C virus (HCV) is a major causative agent of parenterally acquired hepatitis. Vertical transmission of HCV occurs from mother to infant during pregnancy, delivery, or neonatal period. Hepatitis C infection among pregnant females can adversely affect both mother and fetus, leading to chronic infection in infants who later develop liver cirrhosis and hepatocellular carcinoma. Objective of the study was to evaluate the prevalence of hepatitis C among pregnant females attending antenatal clinic.

Methods: A hospital based cross-sectional study was done over a period of six months from January to June 2019. A total of 550 pregnant females were included in the study who attended Antenatal Clinic for routine check-up and whose blood samples were sent to Microbiology Laboratory for screening of anti-HCV antibodies by Enzyme linked Immunosorbent Assay (ELISA) method.

Results: Out of 550 pregnant females tested, 3 were found to be reactive to anti-HCV antibodies by ELISA; hence the prevalence was found to be 0.5%. All 3 seropositive females belonged to age group 26-35 years, were indoor patients (IPD) and belonged to lower socio-economic class. Majority of seropositive females belonged to urban areas (66.7%, 2/3) as compared to those from rural areas (33.3%, 1/3).

Conclusions: Although, prevalence of hepatitis C was found to be less among pregnant females attending ANC of this institute, still routine screening of all pregnant females for anti-HCV antibodies is highly recommended, for timely detection of disease in mothers and prevention of its transmission to infants.

Keywords: Enzyme-linked immunosorbent assay, Hepatitis C, Pregnant females, Prevalence

INTRODUCTION

Hepatitis C virus (HCV) is the major etiological agents of parenteral acquired hepatitis.1 Hepatitis C is found worldwide. The most affected regions are the World Health Organization (WHO) Eastern Mediterranean Region and the WHO European region, with an estimated prevalence in 2015 of 2.3% and 1.5% respectively.
Prevalence of HCV infection in other WHO regions varies from 0.5% to 1.0%. Increasing incidence of hepatitis C infection among pregnant women affecting both mother and fetus during pregnancy have been reported and this can lead to chronic infection in the infant who later develop liver cirrhosis and hepatocellular carcinoma. More than 8% of pregnant women are infected with HCV worldwide. Studies suggest prevalence of HCV among pregnant females to be 0.6% - 2.4%, with overall mother to infant transmission varying from 8% to 15%.

HCV is a single stranded, enveloped RNA virus with a genome organized as 1 nm long open reading frame. Hepatitis C virus has some structural proteins (Core, E1 and E2) which are at the end of the genome and are followed by the nonstructural proteins. Genetic diversity of HCV exhibits by 6 main genotypes and also hypervariable regions within the E2 protein.

Vertical transmission of HCV occurs from mother to infant during pregnancy, delivery, or neonatal period, resulting in hepatitis C infection in children. Not every transmission event result in chronic infection in infants. Hepatitis C can cause acute or chronic hepatitis. Mostly acute hepatitis C is asymptomatic and hence individual is unaware of the underlying infection. Almost 20%-30% of infected cases automatically resolve the virus and remaining 75%-80% of cases progress to chronic hepatitis. Approximately 10%-25% of people with chronic hepatitis C develop cirrhosis and hepatocellular carcinoma, a process that usually takes 20-30 years.

In Central Europe the seroprevalence of anti-HCV antibodies was estimated to be 2.4% and in Eastern Europe 2.9% and in Western Europe 2.4%.

Countries with high prevalence of HCV infection include Egypt >10% or African countries >3%. Countries with lowest seroprevalence of HCV infection include Netherland, Scandinavia <0.5%. In pregnant women seroprevalence of anti-HCV antibody is around 1.03% in India. With rising incidence of HCV a significant number of pregnant women are affected with HCV, and there is little research regarding the impact of HCV on pregnancy out-come in India.

Hence, the present study was done to evaluate the prevalence of Hepatitis C among pregnant females attending Antenatal Clinic of this Institute in Lucknow.

METHODS

A hospital based cross-sectional study was done in the department of Microbiology, over a period of 6 months from January 2019 to June 2019, to determine the prevalence of Hepatitis C among pregnant females attending Antenatal clinic of Integral Institute of Medical Sciences and Research, Lucknow. The study was approved by Institutional Ethical Committee before commencing the study. An informed consent was taken from all pregnant females prior to collection of samples. A pre-designed questionnaire was used to determine the socio-demographic profile of the enrolled patients.

Inclusion criteria

Apparently healthy pregnant females (Outpatient, OP and indoor patients, IP) attending Antenatal clinic who were screened for hepatitis C and who gave their consent were included in this study.

Exclusion criteria

Patients who did not give their consent were excluded.

A total of 550 pregnant females whose blood samples were sent to Microbiology laboratory for anti-HCV antibodies testing were included in the present study.

3ml of venous blood withdrawn aseptically from each pregnant female in a well labeled plain vacutainer tube was received in Microbiology Laboratory. The blood was allowed to clot followed by centrifugation of the tube at 3000 rpm for 15 min to separate serum. The sera was then tested for anti-HCV antibodies by using 3rd generation HCV Microlisa an enzyme linked immunosorbsent assay (ELISA) method (J. Mitra and Company Private Limited, India). The HCV Microlisa is based on detection of host generated anti-HCV antibodies to viral proteins (Core E1, E2 and Non-Structural NS3, NS4 and NS5 antigens) coated into the microwells. The test was performed according to manufacturer’s instruction. 100 µl negative control, 100 µl positive control, 100 µl sample diluent and 10 µl samples were added in the respective wells. The plate was then covered and incubated in an incubator at 37°C±2°C for 30 minutes followed by washing with working wash solution. Then 100 µl working conjugate was added in each well. The plate was again covered and incubated in an incubator at 37°C±2°C for 30 minutes. The plate was then washed with working wash solution followed by the addition of 100 µl working substrate solution in all the wells. The plate was then covered and incubated at room temperature (20-30°C) for 30 minutes in dark. Finally, 100 µl stop solution was added to each well and the absorbance was read at 450 nm in an ELISA reader. The Cut-off value was calculated by multiplying 0.23 with the mean absorbance of Positive control. Samples with absorbance value less than the cut-off value were considered as non-reactive, whereas, those with absorbance value equal to or greater than the cut-off value were considered as reactive by the criteria of HCV Microlisa.

Statistical analysis

The collected data was analyzed using SPSS Data Editor Software version 20. Chi-square test and Fisher’s exact test were performed for categorical variables and p value ≤0.05 were considered statistically significant.
RESULTS

A total of 550 pregnant females included in the study were screened for presence of anti-HCV antibodies. Of these 3 pregnant females were found to be reactive by HCV Microlisa (ELISA), giving the seroprevalence of Hepatitis C to be 0.5% as shown in (Table1).

Table 1: Distribution of pregnant females according to the results of HCV Microlisa (N = 550).

| Result of HCV Microlisa | Number of pregnant females (N) | Percentage (%) |
|-------------------------|--------------------------------|----------------|
| Reactive                | 3                              | 0.5%           |
| Non-reactive            | 547                            | 99.5%          |
| Total                   | 550                            | 100%           |

It was found that majority of pregnant females included in this study belonged to age group 15-25 years (45.3%, 249/550), followed by age group 26-35 years (43.3%, 238/550) and least number belonged to age group 36-45 years (11.4%, 63/550). However, all the 3(100%) reactive female patients belonged to age group 26-35 years, as depicted in (Table 2).

Table 2: Distribution of pregnant females according to their age group and reactivity to HCV Microlisa (N = 550).

| Age group (in yrs) | Result of HCV Microlisa | Total |
|--------------------|-------------------------|-------|
|                    | Reactive N (%)          | Non-reactive N (%) |
| 15-25              | 0 (0%)                  | 249 (100%)       |
| 26-35              | 3 (1.3%)                | 235 (98.7%)      |
| 36-45              | 0 (0%)                  | 63 (100%)        |
| Total              | 3 (0.5%)                | 547 (95.5%)      |

N = Number of pregnant females.

Table 3: Distribution of pregnant females according to their residence and reactivity to HCV Microlisa (N = 550).

| Residence | Result of HCV Microlisa | Total | Chi-Square(χ2) and *p value |
|-----------|-------------------------|-------|-----------------------------|
|           | Reactive N (%)          | Non-reactive N (%) | χ² = 2.52 | df = 1 | p = 0.11 |
| Urban     | 2 (1.4%)                | 141 (98.6%)        | 143 (100%) |       |        |
| Rural     | 1 (0.2%)                | 406 (99.8%)        | 407 (100%) |       |        |
| Total     | 3 (0.5%)                | 547 (99.5%)        | 550 (100%) |       |        |

* p<0.05 was considered as statistically significant. df = degree of freedom, N = Number of pregnant females.

Table 4: Distribution of pregnant females according to their registration status and reactivity to HCV Microlisa (N = 550).

| Registration status | Result of HCV Microlisa | Total |
|---------------------|-------------------------|-------|
|                     | Reactive N (%)          | Non-reactive N (%) | Fisher’s Exact test |
| OPD                 | 0 (0%)                  | 183 (100%)        | p = 0.554 |
| IPD                 | 3 (0.8%)                | 364 (99.2%)       |       |
| Total               | 3 (0.5%)                | 547 (99.5%)       | 550 (100%) |

* p<0.05 was considered as statistically significant. N = Number of pregnant females. OPD = Outpatient department. IPD = Indoor patient department.

Table 5: Distribution of pregnant females according to their socio-economic status and reactivity to HCV Microlisa (N = 550).

| Socio economic status | Result of HCV Microlisa | Total |
|-----------------------|-------------------------|-------|
|                       | Reactive N (%)          | Non-reactive N (%) |
| Upper class           | 0 (0%)                  | 9 (100%)       |
| Middle class          | 0 (0%)                  | 165 (100%)     |
| Lower class           | 3 (0.8%)                | 373 (99.2%)    |
| Total                 | 3 (0.5%)                | 547 (99.5%)    | 550 (100%) |

N = Number of pregnant females.

In this study, although, majority of pregnant females belonged to rural areas (74%, 407/550) as compared to those from urban areas (26%, 143/550), higher number of reactive patients belonged to urban areas (66.7%, 2/3) as compared to those from rural areas (33.3%, 1/3). However, this difference was not found to be statistically significant (p = 0.11) (Table 3).

Table 4 shows, majority of pregnant females belonged to indoor patient department or IPD (66.7%, 367/550) as compared to those who belonged to outpatient department or OPD (33.3%, 183/550). Also, it was found that all 3
reactive patients belonged to IPD. However, this finding was not found to be statistically significant (p = 0.554).

Author found that majority of pregnant females enrolled in this study belonged to lower socio-economic class (68.4%, 376/550), followed by those belonging to middle class (30.0%, 165/550) and least from upper class (1.6%, 9/550). All the 3 reactive females belonged to lower class, as shown in (Table 5).

**DISCUSSION**

HCV infection among pregnant women vary worldwide, from 1% to 2.5% in the United States and Europe to more than 10% in some sub-Saharan countries.\(^2\)\(^3\)\(^2\) In India the overall anti-HCV positivity varies from 0.6% to 1.4%.\(^2\)\(^4\) The epidemiology of HCV varies among countries and the reported prevalence of HCV in pregnant women has not been extensively studied, due to lack of screening of infection and the lack of preventive measures for mother-to-child transmission.\(^2\)\(^5\)

In this study, 550 pregnant females were screened for anti-HCV antibodies, and author found that 3 pregnant females were reactive to HCV by ELISA test, hence the prevalence of HCV infection in pregnant females was 0.5%. A study done from Chennai reported prevalence of HCV among pregnant women to be 0.6%.\(^2\)\(^6\) Another study from Uttarakhand, also reported seroprevalence of hepatitis C to be 0.89% among pregnant women.\(^2\)\(^7\) Both these studies corroborate this finding. However, in contrast to this finding, a study from Sangareddy, Telangana state reported very low prevalence (0.21%) of HCV infection among pregnant women.\(^2\)\(^8\) Similarly, studies from New Delhi and Punjab reported high prevalence of hepatitis C among pregnant women to be 1.03% and 2.8% respectively.\(^2\)\(^9\)

This study found that majority of pregnant females belonged to age group 15-25 years (45.3%,249/550), followed by age group 26-35 years (43.3%,238/550), however, all the 3(100%) reactive female patients belonged to age group 26-35 years. A study from Sangareddy, Telangana state, reported that majority of seropositivity was seen among pregnant women belonging to age group 21-30 years (66.7%,2/3).\(^2\)\(^8\) Another study from Faridkot, Punjab also reported higher seropositivity among pregnant women belonging to age group 21-25 years (45%, 18/40) and 26-30 years (30%, 12/40).\(^2\)\(^9\) These findings were comparable to the present study.

In this study although, majority of pregnant females belonged to rural areas (74%, 407/550) as compared to those from urban areas (26%, 143/550), higher number of reactive patients belonged to urban areas (66.7%, 2/3) as compared to those from rural areas (33.3%, 1/3). In contrast to this finding, a study from Faridkot, Punjab reported higher seropositivity among pregnant women belonging to rural areas (72.5%, 29/40) as compared to those from urban areas (27.5%, 11/40).\(^2\)\(^9\)

In the present study it was found that majority of pregnant females belonged to lower socio-economic class (68.4%, 376/550), followed by those belonging to middle class (30.0%, 165/550) and least from upper class (1.6%, 9/550). All the 3 reactive females belonged to lower class. A study from Chennai also reported that all the 18 reactive pregnant women belonged to lower class and none belonged to upper middle class.\(^2\)\(^6\)

**CONCLUSION**

To conclude, although prevalence of Hepatitis C among pregnant females attending Antenatal clinic of our hospital was less, still routine screening of all pregnant females for anti-HCV antibodies is highly recommended, as early diagnosis of disease in antenatal period is helpful for proper patient management and initiation of treatment to prevent transmission of HCV to newborns. By screening of only at risk females one may miss significant proportion of pregnant women with HCV infection, as majority of pregnant women are asymptomatic, they might not be aware of their infection status and thus transmit their infection to newborns.

_Funding: No funding sources_  
_Conflict of interest: None declared_  
_Ethical approval: The study was approved by the Institutional Ethics Committee_

**REFERENCES**

1. Eriksen NL. Perinatal consequences of hepatitis C. Clin Obstet Gynecol. 1999;42:121-33.
2. World Health Organization: Hepatitis C. WHO Fact Sheet. 2019. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed on 11 September 2019.
3. Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: Screening, treatment, and management. Am J Obstet Gynecol. 2017;217:B2-B12.
4. Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: has anything changed for pregnant/lactating women? World J Hepatol. 2016;8:557-65.
5. Arshad M, El-Kamy SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period—are they opportunities for treatment? J Viral Hepat. 2011;18:229-36.
6. Reddick KLB, Jhaveri R, Gandhi M, James AH, Swamy GK. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat. 2011;18:394-8.
7. Steinmann E, Pietschmann T. Cell culture systems for hepatitis C virus. Curr Top Microbiol Immunol. 2013;369:17-48.
8. Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol. 2013;369:1-15.
9. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012;54:838-55.

10. Ceci O, Margiotta M, Marello F, Francavilla R, Loizzi P, Francavilla A, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr. 2001;33:570-5.

11. Mast EE, Hwang LY, Seto DS, Nolte FS, Nairn OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192:1880-9.

12. Shebl FM, El-Kamary SS, Saleh DA, Abdel-Hamid M, Mikhail N, Allam A, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C virus in rural Egyptian villages. J Med Virol. 2009;81:1024-31.

13. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61:1-32.

14. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62.

15. Kato N. Genome of human hepatitis C virus (HCV): Gene organization, sequence diversity, and variation. Microb Comp Genomics. 2000;5:129-51.

16. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol. 2013;57(4):1333-42.

17. Rantala M van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill. 2008;13(21):18880.

18. Duberg A, Janzon R, Bäck E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill. 2008;13(21):18882.

19. Kumar A, Sharma KA, Gupta RK, Kar P, Chakravarti A. Prevalence and risk factors for hepatitis C virus among pregnant women. Indian J Med Res. 2007;126:211-5.

20. Jaffery T, Tariq N, Ayub R, Yaywar A. Frequency of hepatitis C in pregnancy and pregnancy outcome. J Coll Physicians Surg Pak. 2005;15:716-9.

21. World Health Organization. Global distribution of hepatitis A, B, and C. Wkly Epidemiol Rec. 2002;77:45-7.

22. Boxall E, Skidmore S, Evans C, Nightingale S. The prevalence of hepatitis B and C in an antenatal population of various ethnic origins. Epidemiol Infect. 1994;113:523-8.

23. Goldberg D, McIntyre PG, Smith R, Appleyard K, Dunlop J, Taylor A, et al. Hepatitis C virus among high and low risk pregnant women in Dundee: unlinked anonymous testing. BJOG. 2001;108:365-70.

24. Soood A, Midha V, Bansal M, Sood N, Puri S, Thara A. Perinatal transmission of hepatitis C virus in northern India. Indian J Gastroenterol. 2012;31:27-9.

25. Le Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Pathogenesis of hepatitis C during pregnancy and childhood. Viruses 2012;4:3531-50.

26. Parthiban R, Shanmugam S, Velu V, Nandakumar S, Dhevahi E, Thangaraj K, et al. Transmission of hepatitis C virus from asymptomatic mother to child in southern India. Int J Infect Dis. 2009;13:e394-400.

27. Upreti P, Singh RK, Arya V. Burden of HCV infection among pregnant women with assessment of risk factors and pregnancy outcome in HCV infected: A hospital based study from Uttarakhand. J Med Sci Clin Res. 2017;5:17249-56.

28. Pyadala N, Maity SN, Kothapalli J, Goud AK, Borugadda R, Mallepaddi PC, et al. Seroprevalence of HCV infection among pregnant women in a rural teaching hospital, Sangareddy. Int J Res Develop Pharmacy Life Sci. 2016;5:2251-4.

29. Goyal LD, Kaur S, Jindal N, Kaur H. HCV and Pregnancy: Prevalence, risk factors, and pregnancy outcome in North Indian Population: A Case-Control Study. J Obstet Gynecol India. 2014;64:332-36.

Cite this article as: Jahan N, Chaudhary N, Asma Nigar A, Ahmad S, Khatoon R, Kumar A. Prevalence of hepatitis C among pregnant females attending antenatal clinic at a tertiary Care hospital in Lucknow, Uttar Pradesh, India. Int J Adv Med 2020;7:314-8.